Aclaris Therapeutics Inc (NASDAQ:ACRS)
| 13.00 Delayed Data As of May 27 |  +0.53 / +4.25%Today’s Change | 9.26 Today|||52-Week Range 24.00 | -10.59% Year-to-Date |
Latest ACRS News | Press Releases
| Wall Street Analysts Believe Aclaris (ACRS) Could Rally 179%: Here's is How to Trade May 27 / Zacks.com - Paid Partner Content | Philips' (PHG) Launches a Range of New Products at EuroPCR 2022 May 17 / Zacks.com - Paid Partner Content |
| KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M May 17 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 12.47 |
| Today’s open | 12.57 |
| Day’s range | 12.12 - 13.20 |
| Volume | 337,318 |
| Average volume (3 months) | 475,076 |
| Market cap | $806.3M |
Data as of 05/27/2022
Growth & Valuation
| Earnings growth (last year) | -33.56% |
| Earnings growth (this year) | +4.79% |
| Earnings growth (next 5 years) | +38.60% |
| Revenue growth (last year) | +4.30% |
| P/E ratio | -- |
| Price/Sales | 122.00 |
| Price/Book | 3.76 |
Competitors
| ---- | ||
| CRNXCrinetics Pharmaceut... | -0.33 | -1.93% |
| KURAKura Oncology Inc | +0.96 | +7.65% |
| ENTAEnanta Pharmaceutica... | +1.34 | +3.51% |
Data as of 3:59pm ET, 05/27/2022
Financials
| Next reporting date | August 11, 2022 |
| EPS forecast (this quarter) | -$0.36 |
| Annual revenue (last year) | $6.8M |
| Annual profit (last year) | -$90.9M |
| Net profit margin | -1,343.96% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Wayne, Pennsylvania |
Forecasts
